JPH09510216A - ５−ｈｔ▲下２ｂ▼受容体に関連する病態を治療するための方法 - Google Patents

５−ｈｔ▲下２ｂ▼受容体に関連する病態を治療するための方法

Info

Publication number
JPH09510216A
JPH09510216A JP7523692A JP52369295A JPH09510216A JP H09510216 A JPH09510216 A JP H09510216A JP 7523692 A JP7523692 A JP 7523692A JP 52369295 A JP52369295 A JP 52369295A JP H09510216 A JPH09510216 A JP H09510216A
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
hydrogen
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7523692A
Other languages
English (en)
Japanese (ja)
Inventor
オーディア，ジェイムズ・エドムンド
コーエン、マーレーン・ロイス
ジッダ，ジャスワント・シン
ネルソン，デイビッド・ロイド・ガーバー
ベイカー，スティーブン・リチャード
エスケーラ−カレラ，ヘスス
ラマス−ペテイラ，カルロス
ペドレガル−テルセロ，コンセプシオン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/380,565 external-priority patent/US5663178A/en
Priority claimed from US08/380,566 external-priority patent/US5688807A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH09510216A publication Critical patent/JPH09510216A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP7523692A 1994-03-11 1995-03-10 ５−ｈｔ▲下２ｂ▼受容体に関連する病態を治療するための方法 Pending JPH09510216A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21262294A 1994-03-11 1994-03-11
US08/212,622 1994-03-11
US08/380,565 US5663178A (en) 1995-02-06 1995-02-06 Tetrahydro-beta carbolines
US08/380,566 US5688807A (en) 1994-03-11 1995-02-06 Method for treating 5HT2B receptor related conditions
US08/380,566 1995-02-06
US08/380,565 1995-02-06
PCT/US1995/003099 WO1995024200A1 (en) 1994-03-11 1995-03-10 Method for treating 5ht2b receptor related conditions

Publications (1)

Publication Number Publication Date
JPH09510216A true JPH09510216A (ja) 1997-10-14

Family

ID=27395770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7523692A Pending JPH09510216A (ja) 1994-03-11 1995-03-10 ５−ｈｔ▲下２ｂ▼受容体に関連する病態を治療するための方法

Country Status (11)

Country Link
EP (1) EP0749313A4 (cs)
JP (1) JPH09510216A (cs)
CN (1) CN1148340A (cs)
AU (1) AU679635B2 (cs)
CA (1) CA2185236A1 (cs)
CZ (1) CZ264996A3 (cs)
FI (1) FI963571A7 (cs)
HU (1) HUT75522A (cs)
IL (1) IL112958A0 (cs)
NO (1) NO963785L (cs)
WO (1) WO1995024200A1 (cs)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085510A1 (ja) * 2005-02-08 2006-08-17 Astellas Pharma Inc. 過敏性腸症候群の治療薬
JP2006525972A (ja) * 2003-05-09 2006-11-16 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 食物摂取障害の予防および／または治療用の医薬品製造のためのスルホンアミド誘導体の使用
WO2007097276A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
WO2010058858A1 (ja) 2008-11-21 2010-05-27 ラクオリア創薬株式会社 ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体
US8076348B2 (en) 2005-08-08 2011-12-13 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
JP2013505947A (ja) * 2009-09-23 2013-02-21 メディベイション テクノロジーズ， インコーポレイテッド ピリド［３，４−ｂ］インドールおよび使用方法
JP2013505946A (ja) * 2009-09-23 2013-02-21 メディベイション テクノロジーズ， インコーポレイテッド ピリド［３，４−ｂ］インドールおよび使用方法
US9260429B2 (en) 2008-03-24 2016-02-16 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
JP2022523774A (ja) * 2019-02-27 2022-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
JP2023539949A (ja) * 2020-09-01 2023-09-20 エンベリック バイオサイエンシズ カナダ インコーポレイテッド ハロゲン化シロシビン誘導体および使用方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
AU5317996A (en) * 1995-04-18 1996-11-07 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
GB9523999D0 (en) 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
JP2000507269A (ja) * 1996-03-15 2000-06-13 イーライ・リリー・アンド・カンパニー 一般かぜまたはアレルギー性鼻炎の処置方法
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
UA44838C2 (uk) * 1996-03-25 2002-03-15 Елі Ліллі Енд Компані Спосіб лікування мігрені
IL126062A0 (en) * 1996-03-25 1999-05-09 Lilly Co Eli Tetrahydrobetacarboline compounds
US5886003A (en) * 1996-03-25 1999-03-23 Eli Lilly And Company Methods of treating or ameliorating the symptoms of venomous bites and stings
AU4856600A (en) 1999-05-18 2000-12-05 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
WO2000071517A1 (en) 1999-05-24 2000-11-30 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
SG11201807708SA (en) 2016-04-01 2018-10-30 Zeno Royalties & Milestones Llc Estrogen receptor modulators
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
EP3931189A4 (en) 2019-02-27 2022-11-30 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
AU2020326691A1 (en) 2019-08-06 2022-03-03 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
CA3239565A1 (en) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
WO2023143393A1 (zh) * 2022-01-29 2023-08-03 上海科技大学 三并环类化合物、其制备方法和用途
WO2025137581A1 (en) * 2023-12-21 2025-06-26 Atai Therapeutics, Inc. Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492304A (en) * 1968-06-24 1970-01-27 Warner Lambert Pharmaceutical 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones
DE3240514A1 (de) * 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4520024A (en) * 1983-02-11 1985-05-28 Eli Lilly And Company Method of selectively blocking peripheral vascular serotonergic receptors
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
EP0620222A3 (en) * 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525972A (ja) * 2003-05-09 2006-11-16 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 食物摂取障害の予防および／または治療用の医薬品製造のためのスルホンアミド誘導体の使用
WO2006085510A1 (ja) * 2005-02-08 2006-08-17 Astellas Pharma Inc. 過敏性腸症候群の治療薬
US8076348B2 (en) 2005-08-08 2011-12-13 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
JP5157893B2 (ja) * 2006-02-20 2013-03-06 アステラス製薬株式会社 ピロール誘導体またはその塩
WO2007097276A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
US8222274B2 (en) 2006-02-20 2012-07-17 Astellas Pharma Inc. Pyrrole derivative or salt thereof
US9469641B2 (en) 2008-03-24 2016-10-18 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US9260429B2 (en) 2008-03-24 2016-02-16 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
WO2010058858A1 (ja) 2008-11-21 2010-05-27 ラクオリア創薬株式会社 ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体
JP2013505946A (ja) * 2009-09-23 2013-02-21 メディベイション テクノロジーズ， インコーポレイテッド ピリド［３，４−ｂ］インドールおよび使用方法
JP2013505947A (ja) * 2009-09-23 2013-02-21 メディベイション テクノロジーズ， インコーポレイテッド ピリド［３，４−ｂ］インドールおよび使用方法
JP2022523774A (ja) * 2019-02-27 2022-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
JP2025069411A (ja) * 2019-02-27 2025-04-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
JP2023539949A (ja) * 2020-09-01 2023-09-20 エンベリック バイオサイエンシズ カナダ インコーポレイテッド ハロゲン化シロシビン誘導体および使用方法

Also Published As

Publication number Publication date
HUT75522A (en) 1997-05-28
CN1148340A (zh) 1997-04-23
NO963785D0 (no) 1996-09-10
FI963571A0 (fi) 1996-09-10
IL112958A0 (en) 1995-06-29
CZ264996A3 (cs) 1998-01-14
WO1995024200A1 (en) 1995-09-14
HU9602482D0 (en) 1996-11-28
AU2118695A (en) 1995-09-25
FI963571L (fi) 1996-11-08
AU679635B2 (en) 1997-07-03
CA2185236A1 (en) 1995-09-14
FI963571A7 (fi) 1996-11-08
EP0749313A4 (en) 2001-10-24
NO963785L (no) 1996-11-01
EP0749313A1 (en) 1996-12-27

Similar Documents

Publication Publication Date Title
JPH09510216A (ja) ５−ｈｔ▲下２ｂ▼受容体に関連する病態を治療するための方法
US6090945A (en) Tetrahydro-beta-carbolines
US5705519A (en) Method for treating 5-HT2B receptor related conditions
US5488053A (en) Tetrahydro-pyrido-indole
US5663178A (en) Tetrahydro-beta carbolines
US7166632B2 (en) Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
US5631265A (en) 8-substituted tetrahydro-beta-carbolines
US5869691A (en) Aminoalkyl-indoles
JP2005508969A (ja) ５−ｈｔ活性を有するテトラサイクリックアザインドールおよびインドリン
US5500431A (en) Tetrahydro-β-carbolines
CA2249652A1 (en) Method of treating common cold or allergic rhinitis